Ahead of ad­u­canum­ab fil­ing, Bio­gen nabs Pfiz­er castoff for $75M to ad­dress Alzheimer's, Parkin­son's symp­toms

Bio­gen be­lieves (not every­one agrees) it has a dis­ease-mod­i­fy­ing ther­a­py for Alzheimer’s on the cusp of an FDA ap­proval. Now it’s bring­ing in an ear­ly drug to al­so treat one of its symp­toms.

PF-05251749 is an in­hibitor of ca­sein ki­nase 1, a fam­i­ly of en­zymes key to the reg­u­la­tion of cir­ca­di­an rhythm, that Pfiz­er had tak­en through Phase Ia be­fore culling its en­tire neu­ro­sciences unit. While some as­sets were sal­vaged in the form of a spin­out, this ap­par­ent­ly went up for sale and it’s go­ing for $75 mil­lion up­front. Bio­gen has com­mit­ted to $635 mil­lion in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.